Naevus lightening in melanoma patients under BRAF/MEK inhibitor combination therapy versus checkpoint immunotherapy: A histological and immunohistochemistry analysis

Pigment Cell Melanoma Res. 2018 Mar;31(2):341-344. doi: 10.1111/pcmr.12669. Epub 2017 Nov 27.

Authors

Cathy Yunjia Zhao^{1

2}, Shaun Chou^{1

3}, Rose Congwei Liu^{1

2}, Pablo Fernandez-Peñas^{1

2}

Affiliations

¹ Department of Dermatology, Westmead Hospital, Sydney, NSW, Australia.
² Medicine, University of Sydney, Sydney, NSW, Australia.
³ Institute of Clinical Pathology and Medical Research, Westmead Hospital, Sydney, NSW, Australia.

PMID: 29131505
DOI: 10.1111/pcmr.12669

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Biopsy
Dermoscopy
Humans
Immunohistochemistry
Immunotherapy*
Melanoma / drug therapy*
Melanoma / pathology*
Mitogen-Activated Protein Kinase Kinases / antagonists & inhibitors*
Mitogen-Activated Protein Kinase Kinases / metabolism
Nevus / drug therapy*
Nevus / pathology
Protein Kinase Inhibitors / pharmacology
Protein Kinase Inhibitors / therapeutic use*
Proto-Oncogene Proteins B-raf / antagonists & inhibitors*

Substances

Protein Kinase Inhibitors
BRAF protein, human
Proto-Oncogene Proteins B-raf
Mitogen-Activated Protein Kinase Kinases